KRAS and familial pancreatic carcinoma: Notably, the treatment of these two pancreatic cancer cell lines with extracellular MSN downregulated K-Ras, indicating the outcome of inhibiting K-Ras for preventing the progression of pancreatic cancer cells (Fig. 4H).